This study focuses on ND-340 extended release injection suspension for healthy volunteers with a one-time nerve blockade to determine the safety, tolerability, and pharmacokinetic profile.
The current investigational product, ND-340, is a bupivacaine microsphere injection with an extended release profiling. Lipid microsphere, or liposphere, has been proposed as new type of lipid-based encapsulation system for drug delivery of bioactive compounds especially lipophilic compound. ND-340 has not been studied in human before. However, MARCAINE® and EXPAREL® are both FDA-approved drugs, which contain the same active pharmaceutical ingredient (API) as ND-340, which is bupivacaine. MARCAINE® is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. In this study, Investigators will focus on determining the safety, tolerability, and pharmacokinetic profile of ND-340.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Subjects in this arm will receive a single administration of Marcaine® at the 150 mg. Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).
Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg). ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).
National Taiwan University Hospital
Taipei, Taiwan
Adverse events as assessed by CTCAE v 5.0
Treatment-related adverse events will be analyzed by cohort
Time frame: From administration of ND-340 to 140 hours
Changes in 12-lead ECG and Holter monitor
To definition safety profile in cardiac events, vent. rate, PR interval, QRS duration, QT interval, QTc interval
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hour
Changes in Laboratory test - hematology
Hemoglobin, Hct, RBC count, WBC count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelet count
Time frame: Pre-dose, 140 hour
Changes in Laboratory tests - biochemistry
Albumin, Total protein, ALT, AST, ALP, Total bilirubin, BUN, Serum creatinine, K, Na, Mg, Ca, P, Uric acid, Total cholesterol, HbA1c
Time frame: Pre-dose, 140 hour
Changes in Laboratory tests - urinalysis
pH, Specific gravity, Leukocyte, Erythrocyte, Protein, Glucose
Time frame: Pre-dose, 140 hour
Changes in vital signs
To definition safety profile including body temperature,blood pressure, respiratory rate, pulse rate
Time frame: Screening visit, day 0 (Pre-dose, 60 mins), Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
Changes in physical examination
To definition safety profile including general appearance, HEENT, neck, Lymph nodes, skin, cardiovascular, pulmonary, abdomen, neurological system, musculoskeletal/joints
Time frame: Screening visit, day -1, Day 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The tolerability and maximal tolerated dose (MTD) of ND-340 by dose-limiting toxicities (DLTs)
The incidence of DLT will be summarized by each cohort. The number of subject who has DLT will be summarized by cohorts. and the determination of MTD in this study will be provided.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hour
Cmax
Maximum Plasma Concentration of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
Tmax
Time of peak concentration of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
AUC 0-t
Area under the plasma concentration versus time curve from zero to t of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
AUC 0-∞
Area under the plasma concentration versus time curve from zero to infinity of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
T1/2
Terminal half life of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
CL/F
Clearance/Bioavailability of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
λz
Terminal elimination rate constant
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
Vz/F
Apparent volume of distribution during terminal phase after non-intravenous administration
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
MRT 0-∞
Mean residence time from zero to infinity of ND-340
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
Range of motion of knee
The range of motion (ROM) of knee as measured by knee flexion and extension at baseline and subsequent visits, and the change from baseline will be summarized descriptively by cohorts and drugs(ND-340 or Marcaine®).
Time frame: Pre-dose, 1, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hours
The ambulation distance
The ambulation distance as measured by six-minute walk test (6MWT) at baseline and subsequent visits, and the change from baseline will be summarized descriptively by cohorts and drugs (ND-340 or Marcaine®).
Time frame: Once a day on Pre-dose, Day 1 and Day 2